Articles of interest – International Liver Cancer Association

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Oncology, 18 January 2019

A novel HBx genotype serves as a preoperative predictor and fails to activate the JAK1/STATs pathway in hepatocellular carcinoma

Journal of Hepatology, 14 January 2019

Sport decreases the risk of hepatocellular carcinoma

Journal of Hepatology, 21 December 2018

Influence of HIV infection on the natural history of hepatocellular carcinoma: results from a global multicohort study

Journal of Clinical Oncology, 18 December 2018

Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial

Journal of Hepatology, 6 December 2018

Detection and analysis of circulating epithelial cells in liquid biopsies from patients with liver disease

Gastroeneterology, December 2018

Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib

Journal of Hepatology, October 2018

Microbial fermentation and liver cancer development

Cell., October 2018

Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma

Proceedings of the National Academy of Sciences of the United States of America, 29 October 2018

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Lancet Oncology, May 2018

12 3 4 5 6 7 8 10

page 1 of 10

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search